Physician profile
Gary Lu
NPI 1588906457
$6,042.03
in general payments reported to CMS, 2019-2025
51 companies · $3,116 in 2025
The $3,116 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.49 · 2020: $225 · 2021: $458 · 2022: $1,108 · 2023: $74.42 · 2024: $1,043 · 2025: $3,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258 · Long Term Medical Supply Or Device Loan: $1,863 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,258.10 |
| Long Term Medical Supply Or Device Loan | $1,863.04 |
| Education | $112.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,113.00 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $275.55 | 2022-2025 | Opdivo |
| Incyte Corporation | $263.67 | 2023-2025 | Monjuvi, Monjuvi, Jakafi |
| Eisai INC. | $226.19 | 2020-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Astellas Pharma US INC | $188.24 | 2021 | |
| Janssen Biotech, INC. | $181.82 | 2025 | Rybrevant, Tecvayli, Talvey |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $159.20 | 2022-2025 | Imfinzi, Lynparza |
| Sirtex Medical INC | $152.96 | 2022-2025 | Sir-Spheres Microspheres |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Merck Sharp & Dohme LLC | $139.82 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Genmab U.S., INC. | $124.99 | 2025 | Epkinly |
| Rigel Pharmaceuticals, INC. | $118.52 | 2022 | |
| Myriad Genetic Laboratories, INC. | $117.59 | 2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $115.20 | 2022-2025 | Ojjaara, Jemperli |
| Celgene Corporation | $114.28 | 2022-2025 | Reblozyl, Opdualag |
| Pfizer INC. | $112.21 | 2022-2025 | |
| Daiichi Sankyo INC. | $100.05 | 2022-2025 | Enhertu |
| Seagen INC. | $88.60 | 2022 | |
| Lilly USA, LLC | $82.86 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Array Biopharma INC | $69.44 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Dendreon Pharmaceuticals LLC | $68.49 | 2025 | Provenge |
| Abbvie INC. | $53.03 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.11 | 2025 | Fruzaqla, Iclusig |
| Sobi, INC | $47.70 | 2025 | |
| Aveo Pharmaceuticals, INC. | $46.85 | 2025 | |
| Genzyme Corporation | $44.42 | 2025 | |
| Gilead Sciences, INC. | $41.32 | 2022-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $35.36 | 2025 | Lynozyfic |
| Servier Pharmaceuticals LLC | $32.77 | 2025 | |
| Pharmaessentia USA Corporation | $29.88 | 2022 | |
| Amgen INC. | $29.64 | 2025 | Imdelltra (Amg757), Lumakras |
| Emd Serono, INC. | $27.97 | 2025 | |
| Sumitomo Pharma America, INC. | $27.21 | 2025 | Orgovyx |
| Genentech USA, INC. | $23.38 | 2025 | Phesgo |
| Tempus Ai, INC | $23.19 | 2024 | |
| Geron Corporation | $23.16 | 2025 | Rytelo |
| Ipsen Biopharmaceuticals, INC | $22.36 | 2025 | Onivyde |
| Stemline Therapeutics INC. | $21.72 | 2025 | Orserdu |
| Beone Medicines USA, INC. | $19.82 | 2025 | Tevimbra |
| Alnylam Pharmaceuticals INC. | $18.95 | 2025 | Givlaari |
| Kite Pharma, INC. | $18.82 | 2024 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $18.74 | 2025 | |
| Caris Mpi, INC. | $17.60 | 2025 | Mi Cancer Seek |
| Janssen Pharmaceuticals, INC | $16.49 | 2019 | |
| Taiho Oncology, INC. | $15.86 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.